연구동향 분석

Soluble Expression and Purification of the Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor 2 in Escherichia coli

Jia Wei Xiaodan Cao Shengmin Zhou Chao Chen Haijun Yu Yao Zhou Ping Wang 2015년

논문상세정보
인용/피인용
' Soluble Expression and Purification of the Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor 2 in Escherichia coli' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • anticancer drug screening
  • catalyticdomain
  • e.coliexpressionsystem
  • inhibitors
  • soluble expression
  • vascular endothelial growth factor receptor 2
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
34 0

0.0%

' Soluble Expression and Purification of the Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor 2 in Escherichia coli' 의 참고문헌

  • Vascular endothelial growth factors and receptors:anti-angiogenic therapy in the treatment of cancer
    Tugues S Mol. Aspects. Med 32 : 88 ~ 111 [2011]
  • Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as antiangiogenic agents in cancer therapy
    Veeravagu A Recent. Pat. Anticancer Drug Discov 2 : 59 ~ 71 [2007]
  • Vascular endothelial growth factor (VEGF) in autoimmune diseases
    Carvalho JÉF J. Clin. Immunol 27 : 246 ~ 256 [2007]
  • The biology of VEGF and its receptors
    Ferrara N Nat. Med 9 : 669 ~ 676 [2003]
  • Targeting expression of the catalytic domain of the kinase insert domain receptor (KDR) in the peroxisomes of Pichia pastoris
    Wang Y FEMS Yeast Res 9 : 732 ~ 741 [2009]
  • SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    O’Farrell AM Blood 101 : 3597 ~ 3605 [2003]
  • Role of vascular endothelial growth factor in regulation of physiological angiogenesis
    Ferrara N Am. J. Physiol. Cell Physiol 280 : C1358 ~ C1366 [2001]
  • Role of tyrosine kinase inhibitors in cancer therapy
    Arora A J. Pharmacol. Exp. Ther 315 : 971 ~ 979 [2005]
  • Recombinant protein expression in Escherichia coli
    Baneyx F Curr. Opin. Biotechnol 10 : 411 ~ 421 [1999]
  • Rapid screening for improved solubility of small human proteins produced as fusion proteins in Escherichia coli
    Hammarström M Protein Sci 11 : 313 ~ 321 [2002]
  • Production of soluble mammalian proteins in Escherichia coli: identification of protein features that correlate with successful expression
    Dyson MR BMC. Biotechnol 4 : 32 ~ [2004]
  • PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factorinduced responses and tumor growth after oral administration
    Wood JM Cancer Res 60 : 2178 ~ 2189 [2000]
  • Molecular Cloning: A Laboratory Manual
    Sambrook JR Cold Spring Harbor Laboratory Press [2001]
  • Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening
    Zhong L Biochem. Biophys. Acta 1722 : 254 ~ 261 [2005]
  • Expression and purification of human vascular endothelial growth factor receptor 2 tyrosine kinase in Streptomyces for inhibitor screening
    Liu C Biotechnol. Appl. Biochem 50 : 113 ~ 119 [2008]
  • Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B
    Guo XN Biochem. Biophys. Acta 1673 : 186 ~ 193 [2004]
  • Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice
    Sakurai Y Proc. Natl. Acad. Sci. USA 102 : 1076 ~ 1081 [2005]
  • Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors
    Brignola PS J. Biol. Chem 277 : 1576 ~ 1585 [2002]
  • Comparison of folding rates of homologous prokaryotic and eukaryotic proteins
    Widmann M J. Biol. Chem 275 : 18619 ~ 18622 [2000]
  • Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis
    Parast CV Biochemistry 37 : 16788 ~ 16801 [1998]
  • Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase
    Zhao G Anal. Biochem 360 : 196 ~ 206 [2007]
  • Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor
    Doughervermazen M Biochem. Biophys. Res. Commun 205 : 728 ~ 738 [1994]
  • BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Wilhelm SM Cancer Res 64 : 7099 ~ 7109 [2004]
  • A strategy for high-level expression of soluble and functional human interferon α as a GST-fusion protein in E. coli
    Rabhi-Essafi I Protein Eng. Des. Sel 20 : 201 ~ 209 [2007]